Page last updated: 2024-11-04

LSM-1442

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID2538
CHEMBL ID276820
CHEBI ID91620
SCHEMBL ID2298909

Synonyms (44)

Synonym
4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1h-pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-3,14-dione
bdbm50045363
(20rs)-4-ethyl-4-hydroxy-1,12-dihydro-4h-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
(20r)-4-ethyl-4-hydroxy-1,12-dihydro-4h-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione
HMS3267I18
1h-pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione-, 4-ethyl-4-hydroxy-, (+-)-
(.+-.)-camptothecin
31456-25-4
camptothecin (+)-
camptothecine, (+-)-
nsc-302991
NSC302991 ,
NCI60_002559
SMP2_000016
OPREA1_815005
MAYBRIDGE1_007381
NEURO_000041
HMS562H11
CHEMBL276820 ,
FT-0664215
BCP9000476
FT-0623436
FT-0618395
AKOS015895425
BRD-A30437061-001-01-9
4-ethyl-4-hydroxy-1h-pyrano[3',4':6,7]-indolizino[1,2-b]quinolin-3,14(4h,12h)-dione
VSJKWCGYPAHWDS-UHFFFAOYSA-N
SCHEMBL2298909
DTXSID30274373
(+/-)-camptothecin
CHEBI:91620
4-ethyl-4-hydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, aldrichcpr
4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1h-pyrano[3'4':6,7]indolizino[1,2-b]quinoline-3,14-dione
4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione
Q27163449
lsm-1442
camptothecin, camptotheca acuminata - cas 2114454
BRD-A30437061-001-04-3
4-ethyl-4-hydroxy-3,4,12,14-tetrahydro-1h-pyrano[3'4'
(+/-)-camptothecine;20(rs)-camptothecin;dl-camptothecin
(+/-)campathecin
19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
()campathecin
()-camptothecine;20(rs)-camptothecin;dl-camptothecin
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyranoindolizinoquinoline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 1Homo sapiens (human)IC50 (µMol)1.50000.02101.862610.0000AID210946; AID210947
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (11)

Processvia Protein(s)Taxonomy
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (37)

Assay IDTitleYearJournalArticle
AID1145480Solubility of the compound1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID1145431Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span of host at 5.74 umol/kg, ip relative to control1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID57046The compound was tested for inhibitory activity against DNA relaxation by DNA topoisomerase I at dose 100 uM1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin.
AID9798Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring.
AID234609Tested for (median survival time of treated/control animals) x100 at dosage of 60 mg/kg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues.
AID235764Therapeutic index was measured on P-388 leukemia cells.1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID100153The compound was tested in vivo for life prolongation against mouse L1210 tumor cells; Not tested1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin.
AID1145434Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span of host at 144 umol/kg, ip relative to control1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID210946Inhibition of Topoisomerase I by cleavage complex formation in human HL-60 cells1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.
AID8446In vitro cytotoxicity of compound was tested against 9KB cells.1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID57047The compound was tested for inhibitory activity against DNA relaxation by DNA topoisomerase I at dose 30 uM1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin.
AID42763Compound was evaluated for in vitro antiproliferative activity against CAOV-3 human ovarian cancer cell line1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring.
AID1145436Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span of host at 26.3 umol/kg, ip relative to control1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID95318Compound was evaluated for in vitro antiproliferative activity against KATO-III human gastric cancer cell line1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring.
AID261687Antiproliferative activity against NCI60 cell line2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
AID57044The compound was tested for inhibitory activity against DNA relaxation by DNA topoisomerase I at dose 10 uM1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin.
AID153187The compound was tested in vivo for life prolongation against mouse P388 tumor cells at 8 mg/kg concentration1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin.
AID234602Tested for (median survival time of treated/control animals) x100 at dosage of 120 mg/kg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues.
AID1145435Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span of host at 287 umol/kg, ip relative to control1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID53782Compound was evaluated for in vitro antiproliferative activity against DLD-1 human colon cancer cell line1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring.
AID1145459Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as host survival at 5.74 umol/kg, ip after 30 days1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID1145461Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as host survival at 287 umol/kg, ip after 30 days1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID234606Tested for (median survival time of treated/control animals) x100 at dosage of 30 mg/kg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues.
AID8615The cytotoxic activity was in vitro tested by 9PS assay method1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin.
AID152254This is the dose at which optimal activity was observed against P-388 leukemia cells1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID210947Inhibition of Topoisomerase I by cleavage complex formation in intact human HL-60 cells1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs.
AID1145462Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as host survival at 26.3 umol/kg, ip after 30 days1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID234604Tested for (median survival time of treated/control animals) x100 at dosage of 240 mg/kg1994Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19
Antitumor agents. 7. Synthesis and antitumor activity of novel hexacyclic camptothecin analogues.
AID98220Compound was evaluated for in vitro antiproliferative activity against L1210 mouse leukemia cell line1998Bioorganic & medicinal chemistry letters, Jul-21, Volume: 8, Issue:14
Synthesis and in vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring.
AID1145432Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span of host at 28.7 umol/kg, ip relative to control1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID120239Optimal activity expressed as percentage treated to that of control was measured in vivo against P-388 leukemia cells1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID152255Antileukemic activity against P-388 leukemia cells was measured at given dose range1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID132641The cytotoxic activity in vitro by 9KB assay method1990Journal of medicinal chemistry, Mar, Volume: 33, Issue:3
Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin.
AID261688Activity against NCI60 cell line xenograft in nude mouse by HF assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
AID152253Lowest toxicity was observed at this dose against P-388 leukemia cells1980Journal of medicinal chemistry, May, Volume: 23, Issue:5
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.
AID1145460Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as host survival at 28.7 umol/kg, ip after 30 days1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
AID1145433Antileukemic activity against mouse L1210 cells allografted in BDF1 mouse assessed as increase in life span of host at 71.8 umol/kg, ip relative to control1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Experiments of synthesis of dl-camptothecin. 4. Synthesis and antileukemic activity of dl-camptothecin analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's4 (57.14)18.2507
2000's1 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]